Pulmonary fibrosis is the end stage of a heterogeneous group of disorders and is characterized by the excessive deposition of extracellular matrix proteins within the pulmonary interstitium.
Introduction
The prime function of the coagulation cascade is to generate a stable, insoluble, cross-linked fibrin blood clot to promote haemostasis at sites of vascular injury. T h e formation of the provisional clot, which comprises aggregated platelets enmeshed by fibrin, is critically dependent on the action of thrombin and is generated after the stepwise activation of coagulation proteases via two highly regulated, independent pathways : the extrinsic and intrinsic systems. Briefly, the extrinsic pathway is the trigger mechanism for blood coagulation and is activated when Factor VIIa comes in contact with extravascular tissue factor following vascular injury. Tissue factor and Factor VIIa contribute to the 'extrinsic tenase' complex, which activates Factor X, at the point of convergence with the intrinsic pathway. T h e intrinsic pathway is triggered when blood comes into contact with negatively charged components of subendothelial connective tissue, such as collagen. T h e pathway is initiated by the kallikrein/kinin system and involves sequential activation of Factor XII, Factor XI and Factor IX. Factor IXa, together with Factor VIIIa, contributes to the 'intrinsic tenase' complex and activates Factor X. At this point of the cascade, the extrinsic and intrinsic pathways merge to trigger a set of reactions in the common pathway. Factor Xa then binds to a cell surface receptor called effector protease receptor-1 and forms the prothrombinase complex, which is responsible for the conversion of prothrombin into thrombin. Thrombin cleaves soluble fibrinogen into insoluble fibrin and also activates Factor XI11 which cross-links the fibrin clot and also promotes platelet aggregation, resulting in the formation of stable haemostatic plugs.
Role of the coagulation cascade in pulmonary fibrosis
A number of investigators have shown that activation of the coagulation cascade is a common feature of fibrotic lung disease. For example, intraalveolar accumulation of fibrin has been described for patients with pulmonary fibrosis [l-31, acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) [4, 5] , a condition in which rapid fibroproliferation and matrix synthesis can lead to the development of extensive fibrotic lesions [6] . Furthermore, bronchoalveolar lavage fluid (BALF) from patients with ARDS, has been shown to contain tissue factor-Factor VII/VI Ia complexes, which can activate Factor X, and trigger activation of the extrinsic coagulation cascade [S] .
T h e first evidence that thrombin may be an important mediator in the pathogenesis of fibrotic disease in humans was provided by studies that demonstrated that levels of active thrombin are increased in BALF from patients with pulmonary fibrosis associated with systemic sclerosis [7, 8] . Similar findings were also obtained in the bleomycin model of pulmonary fibrosis [9, 10] . It has been proposed that excessive procoagulant activity in ARDS may be owing to reduced levels of the endogenous thrombin inhibitor, antithrombin I I I [ l l ] . In addition, protein C activity, which indirectly controls thrombin generation by inactivating coagulation protease complexes within both the intrinsic and extrinsic systems, is reduced in patients with interstitial lung disease and is associated with abnormal collagen turnover in the intraalveolar space [ 121.
Several human and animal studies have examined the effects of modulating the coagulation cascade in acute and chronic lung disease. Exogenous delivery of the highly specific direct thrombin inhibitor, hirudin, or antithrombin 111, is protective in animal models of ALI [13-151. In addition, heparin, which inhibits coagulation proteases by potentiating the formation of antithrombin 111-serine protease complexes, leads to improved gas exchange in an animal model of ALI [16] . Finally, heparin has also been shown to attenuate bleomycin-induced pulmonary fibrosis in mice [ 171.
Biological function of thrombin in tissue fibrosis
When the first studies documented that activation of the coagulation cascade was a common feature of fibrotic lung disease, many of the biological effects exerted by thrombin were still unknown. Research performed over the last 10 years has shown that thrombin mediates a number of cellular responses that may play critical roles in tissue repair responses. Most of these cellular effects are mediated by a unique family of ubiquitously expressed cell-surface receptors called proteaseactivated receptors (PARs), which are activated by limited proteolysis rather than direct ligand binding [18] . Although four PARs have been characterized to date, PAR-1 has been shown to be the major receptor involved in mediating thrombin's mitogenic, pro-fibrotic and pro-inflammatory effects in vitro [19-211. After the interaction of thrombin with its receptors, most of its cellular effects are thought to be mediated via the induction and release of a host of secondary mediators [22] . Consistent with this hypothesis, we have shown recently that thrombin is a potent inducer of connective tissue growth factor (CTGF) by human lung fibroblasts via direct proteolytic activation of PAR-1 [23]. C T G F is also induced in response to transforming growth factor PI, the most potent fibrogenic mediator characterized to date [24] . Since both thrombin and transforming growth factor p, induce C T G F production in fibroblasts in uitro, it has been suggested that C T G F may be a common downstream mediator responsible for mediating the profibrotic effects of both molecules (reviewed on pages 194-200 in this issue [25] ).
Thrombin and PAR-I expression in experimental bleomycin-induced pulmonary fibrosis
Recent studies in our laboratory have assessed the role of thrombin and its major cellular receptor, PAR-1, in bleomycin-induced pulmonary fibrosis. Immunohistochemical studies performed to examine the exact localization of thrombin in the lung have shown that there is very weak expression of thrombin on resident alveolar macrophages in the normal lung. However, after bleomycin instillation, expression of thrombin is markedly increased and predominantly localized to macro- and facilitate the local extravascular generation of maximal 6 days after bleomycin instillation, which thrombin, independent of classical blood coaguis in accord with previous reports of peak thromlation. Indirect support that these effects occur in bin levels [9, 10] and procoagulant activity associthe human lung has come from studies showing ated with alveolar macrophages in BALF of that thrombin is present on the surface of normal bleomycin-treated rats [26] . There are a number human alveolar macrophages [30] and that exof potential mechanisms that may lead to increased pression of tissue factor on these cells is increased expression of thrombin on macrophages and interdramatically in patients with pulmonary fibrosis stitial cells following bleomycin injury. For ex- [31] . ample, the active protease may leak into the T h e immunohistochemical localization of alveolar space from the vascular compartment as PAR-1 after bleomycin instillation, similarly to a result of chronic activation of the coagulation thrombin, showed that positive staining was precascade, following the extensive and continued dominately associated with macrophages in inendothelial injury caused by bleomycin. In adterstitial inflammatory and fibroproliferative foci, dition, macrophages and fibroblasts have been but was also present on elongated spindle-shaped shown to express tissue factor, the primary cellcells in these areas (Figure 1 ). PAR-1 was also surface initiator of the extrinsic coagulation consistently expressed on the bronchial epithelium cascade in uitro [27, 28] . Furthermore, macroin sham-treated lung tissue from rats used in this phages express membrane assembly sites for the study, although there was no evidence of altered generation of the prothrombinase complex [29] , expression following saline or bleomycin instilresponsible for activating the intrinsic coagulation lation. 
Thrombin and PAR-I expression is increased in bleomycin-induced pul-
Consistent with our immunohistochemical and produce collagen [32] . There is also evidence findings, PAR-1 mRNA levels were also increased that fibrin can act as a reservoir of fibrogenic in the lungs of bleomycin-treated rats, compared growth factors and cytokines, which are released with animals that were given saline alone. In during fibrinolysis [33] . However, the recent addition, we were able to show that primary observation that fibrinogen knockout mice are not cultures of rat lung fibroblasts grown from shamprotected from developing pulmonary fibrosis in treated rats expressed PAR-1 at the mRNA and response to bleomycin has challenged the role of protein level and that these receptors were funcfibrin in the pathogenesis of this condition [34] . tional in proliferation and C T G F gene expression Given the widespread expression of PAR-1 in studies. T h e combination of these in uiuo and in the interstitial compartment of the lung after vitro findings suggests that the well characterized bleomycin-induced injury, we examined whether PAR-1 -mediated cellular effects of thrombin may thrombin's numerous cellular effects may play an play an important role in this model of pulmonary important role in this experimental model. We fibrosis.
were able to show that the previously reported increases in C T G F and a,(I) procollagen mRNA levels in response to bleomycin-induced lung
Direct thrombin inhibition attenuates
injury [35, 36] were reduced dramatically in rats bleomycin-induced PulmonaV fibrosis that were treated with the direct thrombin inhibiEvaluation of the contribution of thrombin in this tor UK-156406 (see Figure 3) . Indirect support animal model showed that the typical doubling in for the idea that UK-156046 may exert its prototal lung collagen in response to bleomycin tective effects following bleomycin instillation instillation in drug-vehicle control animals was by interfering directly with thrombin-mediated attenuated by up to 40 in animals given a direct fibroblast responses was also provided by in vitro thrombin inhibitor as a continuous subcutaneous studies showing that thrombin-induced effects infusion (Figure 2) . It is likely that thrombin is (fibroblast proliferation and increased procollagen acting via both its procoagulant effects, i.e. fibrin and C T G F mRNA levels) were almost completely deposition, and cellular effects in this model of abolished at UK-156406 concentrations that bleomycin-induced lung injury. Fibrin is thought would be attained at the dose used in this study in to influence the tissue repair/fibrotic response by vivo. Since there is increasing in vitro evidence acting as a provisional matrix in combination with that thrombin exerts its profibrotic effects via the fibronectin, on which fibroblasts can proliferate upregulation of secondary mediators, it is tempt- 
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ing to speculate that the effects of thrombin on lung collagen accumulation may be mediated, at least in part, via a CTGF-dependent mechanism. Future studies, utilizing PAR-1 knockout mice, will be critical in unravelling the contribution of the cellular versus the procoagulant effects of thrombin in promoting lung collagen deposition in this model, and are currently ongoing in our laboratory 
Summary and conclusion
